Tang Haiyang, Yamamura Aya, Yamamura Hisao, Song Shanshan, Fraidenburg Dustin R, Chen Jiwang, Gu Yali, Pohl Nicole M, Zhou Tong, Jiménez-Pérez Laura, Ayon Ramon J, Desai Ankit A, Goltzman David, Rischard Franz, Khalpey Zain, Black Stephan M, Garcia Joe G N, Makino Ayako, Yuan Jason X J
Department of Medicine, Division of Translational and Regenerative Medicine.
Kinjo Gakuin University School of Pharmacy, Nagoya, Japan;
Am J Physiol Lung Cell Mol Physiol. 2016 May 1;310(9):L846-59. doi: 10.1152/ajplung.00050.2016. Epub 2016 Mar 11.
An increase in cytosolic free Ca(2+) concentration ([Ca(2+)]cyt) in pulmonary arterial smooth muscle cells (PASMC) is a major trigger for pulmonary vasoconstriction and a critical stimulation for PASMC proliferation and migration. Previously, we demonstrated that expression and function of calcium sensing receptors (CaSR) in PASMC from patients with idiopathic pulmonary arterial hypertension (IPAH) and animals with experimental pulmonary hypertension (PH) were greater than in PASMC from normal subjects and control animals. However, the mechanisms by which CaSR triggers Ca(2+) influx in PASMC and the implication of CaSR in the development of PH remain elusive. Here, we report that CaSR functionally interacts with TRPC6 to regulate [Ca(2+)]cyt in PASMC. Downregulation of CaSR or TRPC6 with siRNA inhibited Ca(2+)-induced [Ca(2+)]cyt increase in IPAH-PASMC (in which CaSR is upregulated), whereas overexpression of CaSR or TRPC6 enhanced Ca(2+)-induced [Ca(2+)]cyt increase in normal PASMC (in which CaSR expression level is low). The upregulated CaSR in IPAH-PASMC was also associated with enhanced Akt phosphorylation, whereas blockade of CaSR in IPAH-PASMC attenuated cell proliferation. In in vivo experiments, deletion of the CaSR gene in mice (casr(-/-)) significantly inhibited the development and progression of experimental PH and markedly attenuated acute hypoxia-induced pulmonary vasoconstriction. These data indicate that functional interaction of upregulated CaSR and upregulated TRPC6 in PASMC from IPAH patients and animals with experimental PH may play an important role in the development and progression of sustained pulmonary vasoconstriction and pulmonary vascular remodeling. Blockade or downregulation of CaSR and/or TRPC6 with siRNA or miRNA may be a novel therapeutic strategy to develop new drugs for patients with pulmonary arterial hypertension.
肺动脉平滑肌细胞(PASMC)中细胞溶质游离钙(Ca2+)浓度([Ca2+]cyt)的升高是肺血管收缩的主要触发因素,也是PASMC增殖和迁移的关键刺激因素。此前,我们证明特发性肺动脉高压(IPAH)患者和实验性肺动脉高压(PH)动物的PASMC中钙敏感受体(CaSR)的表达和功能高于正常受试者和对照动物的PASMC。然而,CaSR触发PASMC中Ca2+内流的机制以及CaSR在PH发展中的作用仍不清楚。在此,我们报告CaSR与TRPC6在功能上相互作用以调节PASMC中的[Ca2+]cyt。用小干扰RNA(siRNA)下调CaSR或TRPC6可抑制Ca2+诱导的IPAH-PASMC(其中CaSR上调)中[Ca2+]cyt的增加,而CaSR或TRPC6的过表达增强了Ca2+诱导的正常PASMC(其中CaSR表达水平低)中[Ca2+]cyt的增加。IPAH-PASMC中上调的CaSR还与增强的Akt磷酸化相关,而IPAH-PASMC中CaSR的阻断减弱了细胞增殖。在体内实验中,小鼠(casr(-/-))中CaSR基因的缺失显著抑制了实验性PH的发展和进展,并明显减弱了急性缺氧诱导的肺血管收缩。这些数据表明,IPAH患者和实验性PH动物的PASMC中上调的CaSR和上调的TRPC6之间的功能相互作用可能在持续性肺血管收缩和肺血管重塑的发展和进展中起重要作用。用siRNA或微小RNA(miRNA)阻断或下调CaSR和/或TRPC6可能是为肺动脉高压患者开发新药的一种新的治疗策略。